Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271318 · ClinicalTrials.gov registry record · Phase 1
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
A Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, sponsored by TILT Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT05271318 is a Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma that is actively recruiting participants, run by TILT Biotherapeutics. The registered enrollment target is 29 participants, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05271318, a Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, is actively recruiting participants, sponsored by TILT Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Conditions Studied
Interventions
- BIOLOGICAL TILT-123
- BIOLOGICAL pembrolizumab
- DRUG pegylated liposomal doxorubicin
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New York
- Northwell Heatlh/Lenox Hill Hospital - New York
Other
- Docrates Cancer Center - Helsinki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05271318
The ClinicalTrials.gov registry entry for NCT05271318 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (84% lower). The listed sponsor is TILT Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which TILT-123 is the first listed.
NCT05271318 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, New York, Other.
Frequently Asked Questions
What is clinical trial NCT05271318 about?
NCT05271318 is a clinical study titled "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.". This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
What is the current status of trial NCT05271318?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-05-17. Estimated completion is 2027-08.
What conditions does trial NCT05271318 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-refractory Ovarian Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT05271318?
The interventions under investigation include: TILT-123 (BIOLOGICAL), pembrolizumab (BIOLOGICAL), pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT05271318?
This trial is sponsored by TILT Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05271318 being conducted?
This trial has 3 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RECRUITING · Phase 1
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Platinum-resistant Ovarian Cancer
All registered trials for this condition
Platinum-Resistant Fallopian Tube Carcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.